NCT06140875
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Charite University, Berlin, Germany·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Glioblastoma
- Drug/Device/Intervention
- Radiofrequency electromagnetic field treatment
- Study type
- Interventional
- Intervention type
- device
Sponsor & location
- Primary sponsor
- Charite University, Berlin, Germany
- Location
- Berlin, Germany
Timeline & enrollment
- Phase
- N/A
- Start date
- Nov 15, 2023
- End date
- May 14, 2029
- Enrollment
- 26 participants
Primary outcome
PFS at 6 months
Summary
Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with
 glioblastoma
ICD-10 classifications
Malignant neoplasm of brainMalignant neoplasm: Brain, unspecifiedMesotheliomaMalignant neoplasm: Brain stemMalignant neoplasm: Overlapping lesion of brain
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06140875
- Type
- Device Trial
About this record
Access comprehensive clinical trial information for NCT06140875 through Pure Global AI's free database. This phase not specified trial is sponsored by Charite University, Berlin, Germany and is currently Recruiting. The study focuses on Glioblastoma. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.